Cancer Moonshot

White House declares April 2024 as Cancer Prevention and Early Detection Month

Retrieved on: 
Friday, March 29, 2024
Health, Organization, Partnership, Cancer, Cancer Moonshot, Risk, Family, Birth control

Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.

Key Points: 
  • Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.
  • The designation of National Cancer Prevention and Early Detection Month is a collaborative effort spearheaded by the Prevent Cancer Foundation and supported by 84 organizations.
  • This awareness month is a critical step toward reducing the impact of cancer on individuals, families and communities across the U.S.
    “I’m immensely proud of the Foundation for leading a herculean effort in partnership with the White House Cancer Moonshot team to officially recognize April 2024 as the first-ever National Cancer Prevention and Early Detection Month,” says Jody Hoyos, CEO of the Prevent Cancer Foundation.
  • Highlighting progress: Celebrating the tremendous progress made in cancer research and the development of innovative prevention and early detection strategies driven forward by the Cancer Moonshot.

123 Leading Organizations Urge President Biden: Act Now to Eliminate Menthol Cigarettes

Retrieved on: 
Thursday, March 21, 2024
Health, Organization, Tobacco industry, The Washington Post, Tobacco, Health equity, Public, African Americans, Research, Delays, Cancer, Death, Cancer Moonshot, Woman, Smoking, Administration, FDA

Act now to eliminate menthol cigarettes," the ad states.

Key Points: 
  • Act now to eliminate menthol cigarettes," the ad states.
  • Menthol cigarettes are a "starter product" for youth because menthol cools and numbs the throat, masking the harshness of tobacco smoke.
  • Researchers estimate that prohibiting menthol cigarettes will save up to 654,000 lives within 40 years, including 255,000 Black lives.
  • Given these enormous benefits, the Biden Administration has an obligation to issue the final rules prohibiting menthol cigarettes and flavored cigars without further delay.

MEDITECH to Spotlight Intelligent Interoperability at HIMSS24

Retrieved on: 
Thursday, March 7, 2024
Technology, Nanotechnology, Health, Other Health, Artificial Intelligence, Practice Management, Medical Devices, Software, Managed Care, Hospitals, Genetics, Hardware, Data Management, Nursing, Cloud, Google Cloud, FDB, Cardiac catheterization, AI, Structuring, Intelligence, API, Pharmacogenomics, Clinical trial, Cancer Moonshot, FHIR, EHR, SMART, Patient, MEDITECH, OLIS, Electronic health record, FAST, Representational state transfer

As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.

Key Points: 
  • As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.
  • MEDITECH will present its interoperability strategy at the Interoperability Showcase Spotlight Theater on Wednesday, March 13 at 11:15 a.m. in the “Intelligent Interoperability” session.
  • “Intelligent interoperability opens the doors to innovation by leveraging the flexibility and scalability of the cloud , along with modern and open data standards like SMART apps and FHIR APIs.
  • MEDITECH will also share its Canadian interoperability strategy at the “Achieving a Collaborative Approach to Meaningful Interoperability Across Canada” session.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Tuesday, February 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Tuesday, February 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

CancerX Announces Inaugural Start-Up Accelerator Cohort

Retrieved on: 
Monday, February 26, 2024
Honey, Toxicity, AstraZeneca, Blue box, Government, National Cancer Institute, HHS, Organization, Diagnosis, Estate (law), Assistant, Cancer Moonshot, Navya, White, ViVe, Dime, MassChallenge, AWS, Partnership, Mentorship, Cancer, Dell Technologies, Research, CMMI, Intel, NCI, FDA, Senior advisor, Medicare, Executive, Accelerator, ONC, Pharmaceutical industry

BOSTON, Feb. 26, 2024 /PRNewswire/ -- Today on the Central Stage at ViVE 2024, CancerX announced the 16 start-up members of its inaugural Accelerator cohort, launched in partnership with MassChallenge: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, LindAI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, and Xanthos. 

Key Points: 
  • The collaborative environment fostered by this unique Accelerator will promote cross-pollination of ideas within cohort, spurring further innovation."
  • "We are proud to be the first to formalize the support for early-stage digital innovation in oncology through the CancerX Accelerator.
  • CancerX will build on the success of the inaugural round and plans to open Accelerator applications for a second cohort in the fall of this year.
  • For more information about the CancerX Accelerator and updates on future cohorts, please visit the website or sign up to receive CancerX newsletters.

Innsena Announces Impact Partnership with CancerX

Retrieved on: 
Tuesday, February 13, 2024
Technology, Research, Consulting, Other Technology, Health Technology, Professional Services, Health, Science, Oncology, Toxicity, Assistant, Cancer Moonshot, Death, Organization, Public, Patient, Dime, Disease, Insurance, Medicaid, Movement, ONC, Cancer, Partnership, Pharmaceutical industry

Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .

Key Points: 
  • Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .
  • Innsena joins the initiative as its first Impact Supporter.
  • As a CancerX Impact Partner, Innsena will work collaboratively with the public-private partnership to advise on health disparities, the needs of the underserved, access to care and rural and tribal community, and other needs as its programs evolve.
  • “We’re grateful Innsena has chosen to join the CancerX community,” says Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe) , co-host of CancerX.

Record Year Detailed in ISS National Laboratory® Annual Report

Retrieved on: 
Tuesday, February 6, 2024
Osteoporosis, CASIS, SPACE, Growth, United States national laboratories, Research, International Space Station, NIH, LEO, Annual report, Workforce, ISS, Investment, National Institutes of Health, BPS, NSF, Cancer Moonshot, Education, Outline of physical science, Adidas, The Gentle Touch, Culture, Bangladesh Technical Education Board, Biology, Cancer, ISS National Lab, NASA, Pharmaceutical industry

These successes and many others are highlighted in the ISS National Lab Annual Report for FY23 released today by the Center for the Advancement of Science in Space™ (CASIS™).

Key Points: 
  • These successes and many others are highlighted in the ISS National Lab Annual Report for FY23 released today by the Center for the Advancement of Science in Space™ (CASIS™).
  • CASIS has served as manager of the ISS National Lab for 12 years through a Cooperative Agreement with NASA.
  • Some highlights of FY23 accomplishments:
    Last year, 113 ISS National Lab-sponsored payloads were delivered to the space station—the most ever in a single fiscal year.
  • This brings the total number of peer-reviewed articles related to ISS National Lab R&D to more than 350.

Policymakers, Patients, and Industry Join National Minority Quality Forum to Raise Alarm of Cancer Care Disparities in Minoritized Communities to White House Cancer Moonshot

Retrieved on: 
Wednesday, January 24, 2024
Legislation, City, Risk, Moonshot, Soil, Poverty, Groundwater, Health equity, Hazardous waste, Disease, MSN, Notifiable disease, Exact sciences, Atmosphere, Prevalence, African-American neighborhood, Public policy, MDHHS, Alaska Natives, Cancer cluster, Cancer Moonshot, Water, White, Council, Mortality, Patient, MD, RN, Partnership, Attention, American Indians, Breast cancer, Statistics, Sanofi, Pharmaceutical industry

NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address Problem

Key Points: 
  • The report, entitled Cancer Moonshot, Public Policy, and Medically Underserved Cancer Care Communities, raises a national alarm about disparities in cancer risk, screening, prevalence, and mortality prevalent in medically underserved communities across the United States.
  • This proximity increases cancer risk for these communities, shedding light on an environmental justice issue that demands immediate attention.
  • This has led to later-stage diagnoses, hindering timely access to care and treatment for these communities.
  • We echo President Biden's call to action and emphasize that achieving the vision of the Cancer Moonshot requires urgent and sustained attention to cancer disparities.

GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform

Retrieved on: 
Monday, January 8, 2024
Partnership, Health, HER2, IND, Immunohistochemistry, Research, Cancer Moonshot, McKinsey & Company, Cancer, Digital, Laboratory, AI, IHC, Patient, Safety, MFDS, NK

YONGIN, South Korea and SYDNEY, Jan. 8, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer.

Key Points: 
  • After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer.
  • "Our preclinical studies suggest the possibility that AB-201 causes complete cancer remission and tumor suppression," remarked James Park, CEO of GC Cell.
  • With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations.
  • It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions.